1. 37OSubgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries. (24th November 2019) Authors: Iwata, H; Im, S-A; Sohn, J; Jung, K H; Im, Y-H; Lee, K S; Inoue, K; Tamura, K; Wong, A; Emens, L A; Barrios, C H; Adams, S; Schneeweiss, A; Diéras, V; Winer, E P; Chui, S Y; Henschel, V; Rugo, H S; Loi, S; Schmid, P Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 47O Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice. (15th December 2019) Authors: Drakaki, A; Luhn, P; Wakelee, H; Dhillon, P K; Kent, M; Shim, J; Degaonkar, V; Hoang, T; McNally, V; Chui, S Y; Gutzmer, R Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LBA1_PRIMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). (23rd October 2018) Authors: Schmid, P; Adams, S; Rugo, H S; Schneeweiss, A; Barrios, C H; Iwata, H; Dieras, V; Hegg, R; Im, S-A; Wright, G S; Henschel, V; Molinero, L; Chui, S Y; Funke, R; Husain, A; Winer, E P; Loi, S; Emens, L A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗